

Please add the following new abstract at the last page of the specification:

Chemical structure of a substituted morpholine derivative. The morpholine ring is substituted at the 2-position with a group  $(\text{CH}_2)_q$ , which is further substituted with a group  $(\text{R}^2)_n$ . The morpholine ring is also substituted at the 3-position with a group  $(\text{R}^1)_m$ . The morpholine ring is substituted at the 4-position with a group  $\text{R}^4$ . The morpholine ring is substituted at the 5-position with a group  $\text{R}^5$ . The morpholine ring is substituted at the 6-position with a group  $\text{R}^6$ . The morpholine ring is substituted at the 7-position with a group  $\text{R}^7$ . The morpholine ring is substituted at the 8-position with a group  $\text{R}^8$ . The morpholine ring is substituted at the 9-position with a group  $(\text{R}^9)_t$ .

wherein m R<sup>1</sup>, n, R<sup>2</sup>, q, X, Y, Z, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, t, and R<sup>9</sup> are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.